Organovo, Inc. has been an operating company in San Diego, California since 2009 and currently operates as a fully owned subsidiary of Organovo Holdings, Inc. As a vehicle to provide capital for Organovo, Inc.’s operations and to provide access to public markets for equity securities, Organovo, Inc. entered into a reverse merger with Organovo Holdings, Inc. in February 2012 concurrent with a private placement financing. Organovo Holdings, Inc. was a publicly traded shell company before completion of the reverse merger. Upon effectiveness of the reverse merger, former officers and directors of Organovo Holdings, Inc. resigned their positions and officers and directors associated with Organovo, Inc. assumed control of Organovo Holdings, Inc.

As discussed in our press releases and SEC filings, we have conducted and intend to continue to conduct in-depth research studies. We won’t publish everything we do in our labs given the proprietary nature of our work, but we have published a significant number of these studies. Our 8-K filings and press releases have featured brief descriptions of these studies including our presentation of scientific results at various scientific and technical conferences. In addition, there are many peer-reviewed journal publications on our core technology. We anticipate additional publications in the future. Please see Technology Platform Publications for a comprehensive list of publications and white papers on our science and technology.

Our headquarters is located in San Diego, California.

The common stock of Organovo Holdings, Inc. became publicly traded in the OTC market on February 14, 2012.

Organovo’s common stock trades on the NASDAQ Stock Market under the ticker symbol ONVO.

Our CUSIP is 68620A203.

Our fiscal year ends on March 31. Our quarters end on June 30, September 30, December 31 and March 31. We typically report earnings in connection with the filing of our Annual and Quarterly Reports (Form 10-K or Form 10-Q). In general, we are required to file a Quarterly Report on Form 10-Q within 40 days from December 31, June 30, and September 30, and an Annual Report on Form 10-K within 70 days of March 31 each year. You can find our earnings webcast in the Events and Quarterly Results sections of our website.

Our annual and quarterly reports, proxy statements, earnings reports and other SEC filings are available for viewing and downloading in the SEC Filings and Quarterly Results sections of our website. These documents are also available at www.sec.gov. If you would like a hard copy of our investor kit or any of these documents, you can e-mail info@organovo.com or fill out the request form at Contact Us.

We will announce the date of our Annual Meeting of Stockholders in the proxy statement we provide to our stockholders and file with the SEC for the relevant year.

No. Organovo does not have a direct stock purchase plan. You may purchase Organovo’s common stock through a registered brokerage or stock purchase service provider of your choice.

No. We have never declared or paid a cash dividend for our common stock, nor do we expect to pay any cash dividends for our common stock in the foreseeable future.

Continental Stock Transfer and Trust. They can be reached at http://www.continentalstock.com/ or 1-800-509-5586.

A transfer agent is a regulated organization that keeps track of registered stockholder records and information (including change of address, telephone number and name), canceling or issuing stock certificates and resolving problems related to lost, destroyed or stolen certificates. If your shares are held in street name (i.e. by your broker), you must contact your broker for these services.

Mayer Hoffman McCann P.C. serves as Organovo’s independent auditor.

Paul Hastings, LLP serves as Organovo’s securities counsel.

Please see Board of Directors.